GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Seeking Alpha's Quant system consistently outperforms the S&P 500 ( SP500 ), driven by powerful computer processing and SA's ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

A proposed bill at the Indiana statehouse could mean anyone under the age of 16 could need to get parents approval before downloading social media apps. “We need the IEDC,” said State Senator ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... ll have a lot of winners with these drug and medical device plays.” For this article, we compiled a list ...

Eli Lilly and Company (LLY) is a global leader in healthcare ... medicines to address some of the world's most pressing medical needs. With a market cap of $759.4 billion, Eli Lilly operates ...

Enter Eli Lilly (NYSE ... of overblown panic selling, Lilly's progress against Wegovy -- combined with its diverse and growing medical portfolio -- make the company hard to pass up.